PDF
ePub
Citation
Print
Abstract
Post-marketing safety studies are an important tool for understanding and monitoring the safety profiles of drugs in the clinical setting. Their importance has attracted not only the attention of regulators for reinforcing legislation but also led to recent changes in European Union (EU) regulations; these regulations have influenced the practice of Post-Authorization Safety Study (PASS) by marketing authorization holders. Korea conducts post-marketing surveillance (PMS) studies, but their execution is very different. This editorial reviews the PMS system in Korea in comparison with the recent legislative changes affecting the EU system. Ultimately, it suggests that changes to the PMS system are necessary to obtain quality safety data while maintaining a global standard of operation. Such efforts to refine the system will enhance the credibility of the PMS in Korea and, in due course, produce safety profiles that will be valuable for public health.
References
1. Borg JJ, Aislaitner G, Pirozynski M, Mifsud S. Strengthening and rationalizing pharmacovigilance in the EU: where is Europe heading to? A review of the new EU legislation on pharmacovigilance. Drug Saf. 2011; 34:187–197.
2. Borg JJ, Tanti A, Kouvelas D, Lungu C, Pirozynski M, Serracino-Inglott A, et al. European Union pharmacovigilance capabilities: potential for the new legislation. Ther Adv Drug Saf. 2015; 6:120–140.
3. Choi NK, Park BJ. Adverse drug reaction surveillance system in Korea. J Prev Med Public Health. 2007; 40:278–284.
4. Ministry of Food and Drug Safety (MFDS). Provision of safety information management regulation of drugs. MFDS Notice No. 2015–79 (Amended on Oct 30, 2015).
5. Ministry of Food and Drug Safety (MFDS). Product license information. http://www.mfds.go.kr/index.do?searchkey=title. contents&mid=686&page No=9&seq=10094&cmd=v (Accessed 10 May 2016).
6. Sanofi Pasteur. Avaxim® 80U Pediatric inj. package insert. Reston: Sanofi Pasteur;2013a. http://www.sanofi.co.kr/l/kr/ko/layout.jsp?scat=10454F71-A809–4756–8DE2-CC39058A486D. (Accessed Jan 20, 2016).
7. Epaxal® Berna prefilled syringe inj. Package insert. Seoul: Berna Biotech Korea;http://www.bernabiotech.co.kr/home/da/epaxal_berna.pdf. (Acces-sed May 16, 2016).
8. Sanofi Pasteur. Vaxigrip® package insert. Seoul: Sanofi Pasteur;http://www.sanofi.co.kr/l/kr/ko/layout.jsp?scat=70037095-FBA3-47A5–9282–66B6C399653A. (Accessed Jan 20, 2016).
9. Inflexal® V prefilled syringe inj. Summarized Information. http://www.dru-ginfo.co.kr/cp/msdNew/detail/product_cp.aspx?cppid=186717. (Accessed May 18, 2016).
10. FIRSTHIB INJ. Summarized Information. http://www.druginfo.co.kr/detail/product.aspx?pid=50149. (Accessed May 18, 2016).
11. Song H, Bock H, Guadagno A, Costantini M, Baehner F, Kim YH, et al. Safety of a CRM197-conjugated Haemophilus influenzae type b vaccine in Korean children. Southeast Asian J Trop Med Public Health. 2015; 46:743–752.
12. Hatz C, Beck B, Steffen R, Genton B, d'Acremont V, Loutan L, et al. Real-life versus package insert: a postmarketing study on adverse-event rates of the virosomal hepatitis A vaccine Epaxal® in healthy travellers. Vaccine. 2011; 29:5000–5006.
13. Choi JW, Kim MS, Ma SH, Kang JH, Ok JJ, Ng LT, et al. Post-marketing surveillance study of hepatitis A vaccine in Korean population. Korean J Pediatr Infect Dis. 2008; 15:115–120.
Table 1.
Examples of large discrepancies in the adverse events (AE) rates obtained after PMS in Korea
XML Download